NBTX logo

NANOBIOTIX SA - ADR

NBTXNASDAQ
🏆 #2098 by market capEarnings Apr 27US Equity
$34.06▲ $0.38 (+1.13%)
Market closed · at close
🔔
Track NBTX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.1%
7d▲ 16.3%
14d▲ 59.5%
30d▲ 6.7%
ytd▲ 46.8%
1y▲ 84.7%
🏦Market Cap
$1.58B
Small Cap
📈Revenue Growth (YoY)
512.3%
High Growth
📊Gross Margin
100.0%
High
💵FCF Margin
-456.6%
Thin
⚖️P/S Ratio
180.3x
Expensive
Otter Score
64
Fair

Trading Snapshot

Day Range
$33.32 – $34.06
52-Week Range
$17.37 – $57.14
Volume (shares)
3,957
Avg Volume (shares)
—
Shares Outstanding
46.4M
Next Earnings
2027-04-27

Fundamentals Snapshot

Annual Revenue
$30M
Last Q Revenue
$6M
P/E Ratio
-27.6
P/S Ratio
180.3x
EPS (TTM)
$-1.08
Dividend Yield
0.00%
Dilution (1yr)
+1.2%
NBTX logo

NANOBIOTIX SA - ADR

NBTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$30M▼ −512.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$11M▼ −84.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$34M▲ +66.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
47.8M▲ +1.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$43M▼ −$41M YoY
StockOtter · stockotter.space

About NANOBIOTIX SA - ADR

Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Ratings

ⓘ
Consensus
Buy
12 analysts
Strong Buy5
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.